Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The factors underlying the large interindividual variability in response to glucocorticoids
in Giant Cell Arteritis are poorly understood. The investigators hypothesize that a part of
this variability is related to pharmacokinetic factors determined by genetic polymorphism:
hepatic clearance involving cytochromes P450 of the subfamily 3A (CYP3A) and drug efflux
leukocyte conditioned by P-glycoprotein involved in multidrug resistance drugs (ABCB1). The
investigators have designed a multicentric prospective pharmacokinetical and pharmacogenetic
cohort study to assess the link between prednisolone clearance and the relapse risk in giant
cell arteritis.